Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study

Trial Profile

Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Cangrelor (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Acronyms CANTIC
  • Most Recent Events

    • 11 Jan 2019 Results published in the Circulation
    • 13 Dec 2018 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top